Red Cedar Investment Management LLC Acquires 6,959 Shares of Merck & Co., Inc. $MRK

Red Cedar Investment Management LLC grew its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 33.2% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 27,931 shares of the company’s stock after purchasing an additional 6,959 shares during the period. Red Cedar Investment Management LLC’s holdings in Merck & Co., Inc. were worth $4,059,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. BlackRock Inc. grew its holdings in shares of Merck & Co., Inc. by 0.5% in the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock valued at $29,169,479,000 after acquiring an additional 1,073,507 shares in the last quarter. State Street Corp increased its position in shares of Merck & Co., Inc. by 0.9% in the second quarter. State Street Corp now owns 120,413,256 shares of the company’s stock valued at $15,573,754,000 after acquiring an additional 1,087,583 shares during the last quarter. Wellington Management Group LLP raised its holdings in Merck & Co., Inc. by 2.3% during the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock worth $11,083,033,000 after acquiring an additional 1,934,312 shares in the last quarter. Bank of America Corp DE raised its holdings in Merck & Co., Inc. by 10.5% during the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock worth $3,701,831,000 after acquiring an additional 2,919,780 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Merck & Co., Inc. by 23.8% during the first quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock worth $1,858,938,000 after acquiring an additional 2,969,856 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 11,699 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total value of $1,539,939.37. Following the sale, the executive vice president owned 110,167 shares in the company, valued at $14,501,282.21. This represents a 9.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Jennifer Zachary sold 80,315 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the sale, the executive vice president owned 45,509 shares in the company, valued at $6,073,631.14. This represents a 63.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 102,014 shares of company stock worth $13,608,779. Company insiders own 0.17% of the company’s stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported positive Phase 2b results for efinopegdutide, an investigational weekly treatment for adults with MASH and stage F2 or F3 liver fibrosis. The findings add a potential new opportunity in liver disease, although the supplied report does not include detailed efficacy results. Article: Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide
• Positive Sentiment: Merck has started the Phase 3 ENHANCE-3 trial of OHTUVAYRE for COPD maintenance treatment. Separately, the FDA granted priority review to sacituzumab tirumotecan for endometrial cancer, advancing two potential growth drivers. Article: Merck Starts ENHANCE 3 COPD Trial As Cancer Drug Review Nears
• Neutral Sentiment: Merck’s collaboration with Tempus AI is expected to contribute to a five-year partnership value of roughly $192.5 million, providing a data and AI-related research tie-up; the article does not detail the financial impact to Merck. Article: The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
• Negative Sentiment: Analysts describe Merck’s 2027 growth outlook as challenging, citing generic competition, weaker vaccine performance and slowing growth for Keytruda. These pressures could weigh on near-term results, despite the company’s expanding pipeline. Article: MRK’s 2027 Outlook Challenging, Long-Term Prospects Promising

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $148.49 on Tuesday. The firm has a 50-day moving average of $146.39 and a 200-day moving average of $127.82. Merck & Co., Inc. has a one year low of $85.80 and a one year high of $156.92. The company has a market cap of $366.34 billion, a PE ratio of 153.08, a price-to-earnings-growth ratio of 6.83 and a beta of 0.13. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.09 by $0.40. The company had revenue of $18.09 billion for the quarter, compared to analyst estimates of $17.33 billion. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.56%. Merck & Co., Inc.’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period in the previous year, the business earned $2.58 EPS. As a group, equities analysts forecast that Merck & Co., Inc. will post 2.84 earnings per share for the current year.

Wall Street Analyst Weigh In

MRK has been the subject of several recent research reports. Guggenheim increased their price target on Merck & Co., Inc. from $170.00 to $171.00 and gave the company a “buy” rating in a research report on Friday, October 30th. BMO Capital Markets boosted their price target on Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, August 20th. Cantor Fitzgerald boosted their price target on Merck & Co., Inc. from $145.00 to $155.00 and gave the stock a “neutral” rating in a research report on Monday, November 2nd. DZ Bank cut Merck & Co., Inc. from a “buy” rating to a “hold” rating and set a $153.00 price objective on the stock. in a research note on Tuesday, November 3rd. Finally, Jefferies Financial Group upped their price objective on Merck & Co., Inc. from $152.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $155.74.

About Merck & Co., Inc.

Merck & Co, Inc is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine.

Founded in the United States in 1891, Merck & Co became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.